Cadence Pharmaceuticals, (FRA:QEW) Forward Dividend Yield % : 0.00% (As of Sep. 24, 2024)

View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, Forward Dividend Yield %?

As of today (2024-09-24), the Forward Annual Dividend Yield of Cadence Pharmaceuticals, is 0.00%.

As of today (2024-09-24), the Trailing Annual Dividend Yield of Cadence Pharmaceuticals, is 0.00%.

FRA:QEW's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.575
* Ranked among companies with meaningful Forward Dividend Yield % only.

Cadence Pharmaceuticals,'s Dividends per Share for the three months ended in Dec. 2013 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Cadence Pharmaceuticals,'s Forward Dividend Yield %

For the Biotechnology subindustry, Cadence Pharmaceuticals,'s Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cadence Pharmaceuticals,'s Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadence Pharmaceuticals,'s Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Cadence Pharmaceuticals,'s Forward Dividend Yield % falls into.

Cadence Pharmaceuticals, Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Cadence Pharmaceuticals, (FRA:QEW) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Cadence Pharmaceuticals, Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cadence Pharmaceuticals, Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cadencepharm.com

Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, Headlines

No Headlines